Application of AI/ML technology and a burst of M&A activity look to be shaping the future of the pharma industry.
Novo Nordisk will use the DKK 8.5 billion (US$1.2 billion) to build a new modular and flexible production facility in Odense, Denmark, that will produce multiple products for rare diseases.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback